┌──────────────────────────────────────────────────────────────┐ RECORD TYPE ......... SUBJECT FILE SUBJECT TYPE ........ ORG FILE OPENED ......... 2026-07-05 17:23 UTC APPEARANCES ......... 4 ANNOTATIONS KNOWN ALIASES ....... 1 └──────────────────────────────────────────────────────────────┘
GlaxoSmithKline
ALSO APPEARS AS
- GlaxoSmithKline
APPEARS IN THE MARGINS OF
- Paroxetine Prescriptions for Adolescents (2001-2015) After Study 329 Publication
Study 329 was a clinical trial of paroxetine and imipramine in adolescents with major depression, funded by SmithKline Beecham and published in 2001. The original publication by Keller and colleagues …
- Martin Keller's Role and Statements in Study 329 Paroxetine Trial
Study 329 was a clinical trial conducted from 1994 to 1998 to evaluate the efficacy of paroxetine (Paxil/Seroxat), an SSRI antidepressant, for major depressive disorder in adolescents aged 12-18 [2, 6…
- GlaxoSmithKline Study 329: Ghostwriting and Non-Disclosure Claims
Study 329 was a clinical trial of the antidepressant Paxil (paroxetine) conducted by SmithKline Beecham (now GlaxoSmithKline) between 1994 and 1998, comparing it to Tofranil and placebo in depressed c…
- Pharmaceutical Industry Transparency Guidelines Post-Study 329 Scrutiny
Following significant scrutiny over the transparency of clinical trial data, particularly concerning GlaxoSmithKline's Study 329, pharmaceutical industry bodies have committed to enhanced data sharing…